Home Blog of Signal Transduction Angiogenesis BTK A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome

Currently, there is no effective treatment for refractory/relapsed (R/R) autoimmune haemolytic anaemia (AIHA), associated with poor quality of life. Bruton tyrosine kinase inhibitors have begun to be used in some autoimmune diseases. We initiated the clinical trial of orelabrutinib treatment on R/R AIHA/Evans Syndrome, which is in progress. The preliminary results showed that nine of the 12 enrolled patients responded to orelabrutinib treatment. Here, we reported three cases who have completed the treatment and were followed up for 6 months, achieving complete or partial remission. Orelabrutinib is expected to become a new second-line treatment for R/R AIHA/Evans syndrome.

 

Comments:

That's fascinating! The early results from your clinical trial with orelabrutinib sound promising. Achieving a positive response in nine out of twelve enrolled patients is a significant development, especially in refractory/relapsed cases of autoimmune hemolytic anemia (AIHA) and Evans syndrome. It's great to hear that three cases have completed treatment and sustained their remission over a six-month follow-up period.

If these results continue to show efficacy and safety over a larger patient cohort, orelabrutinib could indeed offer a new avenue for managing R/R AIHA and Evans syndrome as a second-line treatment. This could potentially improve the quality of life for individuals dealing with these conditions. Are there any specific challenges or notable observations you've encountered during the trial that you're addressing in your ongoing research?

Related Products

Cat.No. Product Name Information
S9600 Orelabrutinib Orelabrutinib is a potent, orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). Orelabrutinib has potential antineoplastic activity.

Related Targets

BTK